Department of Mechanical Engineering, University College London, London, UK.
Department of Renal Medicine, Division of Medicine, University College London, London, UK.
J Control Release. 2020 Dec 10;328:490-502. doi: 10.1016/j.jconrel.2020.08.048. Epub 2020 Sep 1.
A significant proportion of urinary tract infection (UTI) patients experience recurrent episodes, due to deep tissue infection and treatment-resistant bacterial reservoirs. Direct bladder instillation of antibiotics has proved disappointing in treating UTI, likely due to the failure of infused antibiotics to penetrate the bladder epithelium and accumulate to high enough levels to kill intracellular bacteria. This work investigates the use of nitrofurantoin loaded poly(lactic-co-glycolic acid) (PLGA) particles to improve delivery to intracellular targets for the treatment of chronic UTI. Using electrohydrodynamic atomisation, we produced particles with an average diameter of 2.8 μm. In broth culture experiments, the biodegradable particles were effective against a number of UTI-relevant bacterial strains. Dye-loaded particles demonstrated that intracellular delivery was achieved in all cells in 2D cultures of a human bladder epithelial progenitor cell line in a dose-dependent manner, achieving far higher efficiency and concentration than equivalent quantities of free drug. Time-lapse video microscopy confirmed that delivery occurred within 30 min of administration, to 100% of cells. Moreover, the particles were able to deliver the drug to cells through multiple layers of a 3D human bladder organoid model causing minimal cell toxicity, displaying superior killing of bacterial reservoirs harboured within bladder cells compared with unencapsulated drug. The particles were also able to kill bacterial biofilms more effectively than the free drug. These results illustrate the potential for using antibiotic-loaded microparticles to effectively treat chronic UTIs. Such a delivery method could be extrapolated to other clinical indications where robust intracellular delivery is required, such as oncology and gene therapy.
相当一部分尿路感染(UTI)患者由于深部组织感染和治疗耐药的细菌库而经历反复发作。抗生素直接膀胱灌注在治疗 UTI 方面效果不佳,可能是由于注入的抗生素无法穿透膀胱上皮并积累到足以杀死细胞内细菌的足够高的水平。这项工作研究了使用负载硝基呋喃妥因的聚(乳酸-共-羟基乙酸)(PLGA)颗粒来改善针对慢性 UTI 的细胞内靶标的递送。使用电动力学雾化,我们生产出平均直径为 2.8μm 的颗粒。在肉汤培养实验中,可生物降解的颗粒对多种与 UTI 相关的细菌菌株有效。负载染料的颗粒表明,在人膀胱上皮祖细胞系的 2D 培养物中,以剂量依赖的方式实现了所有细胞的细胞内递药,其效率和浓度远远高于等量的游离药物。延时视频显微镜证实,给药后 30 分钟内,所有细胞均能递药,达到 100%。此外,这些颗粒能够将药物递送至穿过 3D 人膀胱类器官模型的多个细胞层,对细胞的毒性极小,与未包封的药物相比,能够更有效地杀死膀胱细胞内藏匿的细菌库。这些颗粒还能够比游离药物更有效地杀死细菌生物膜。这些结果说明了使用负载抗生素的微粒有效治疗慢性 UTI 的潜力。这种递药方法可以推广到其他需要稳健细胞内递药的临床适应症,如肿瘤学和基因治疗。